The 28th JFCR－ISCC
December 11-12, 2024
Miraikan - The National Museum of Emerging Science and Innovation 7F
2-3-6, Aomi, Koto-ku, Tokyo, Japan
December 11
12:00-12:30
Committee meeting
Opening Remark
13:00-13:10
Naoya Fujita (Cancer Chemotherapy Center, JFCR, Tokyo)
Opening remark
Session I: Drugging the “undruggable” target (Cystein map）
Chairpersons: Yves Pommier (National Cancer Institute, NIH, Bethesda, MD, USA),
Hiroyuki Seimiya (Cancer Chemotherapy Center, JFCR, Tokyo)
13:10-13:50
Liron Bar-Peled (The Krantz Family Center For Cancer Research, Massachusetts General Hostpital/Harvard Medical School, Boston, MA, USA)
An ‘omics approach to drug discover
13:50-14:20
Makoto Yamagishi (The University of Tokyo, Tokyo)
Valemetostat (first-in-class EZH1/2 inhibitor) as an epigenetic drug discovery from Japan
14:20-15:00
Ryan B. Corcoran (Massachusetts General Hospital Cancer Center, Boston, MA, USA)
No longer undruggable: advances in targeting KRAS
15:00-15:10
Discussion
15:10-15:20
Coffee Break
Session II: Cancer Vaccine
Chairpersons: Yoshihiro Hayakawa (University of Toyama, Toyama),
Kazuma Kiyotani ( National Institutes of Biomedical Innovation, Health and Nutrition, Osaka)
15:20-15:50
Kaku Saito (Moderna Japan, Tokyo)
Development of individualized neoantigen therapy
15:50-16:20
Hiroshi Abe (Nagoya University, Aichi)
Rapid preparation of chemically synthesized mRNA for cancer vaccine
16:20-16:30
Discussion
Special Lecture
Chairperson: Shunji Takahashi (Cancer Institute Hospital, JFCR, Tokyo)
16:30-17:20
Yves Pommier (National Cancer Institute, NIH, Bethesda, MD, USA)
Development of topoisomerase I inhibitors as antibody drug conjugates: From molecular pharmacology to predictive biomarkers
Poster Flash Talk
Chairperson: Manabu Kawada (Institute of Microbial Chemistry, Tokyo)
17:20-18:10
Poster presentors
Poster Viewing & networking
18:10-19:30
Masato Saito (The University of Tokyo, Tokyo)
Identification of p21-positive immature osteoblasts as potential cells of origin for osteosarcomas
Yoshiki Nonaka (Osaka Metropolitan University, Osaka)
Single cell-based analysis of tumor microenvironmental heterogeneity in the progression of MASLD/MASH HCC
Masahisa Hemmi (Astellas Pharma Inc., Ibaraki)
Spatial transcriptomics to reveal the mechanisms of immunomodulation therapy
Tsunaki Hongu (Kanazawa University, Ishikawa)
Mitochondrial one-carbon metabolic enzyme SHMT2 as a therapeutic target for cancer
Keisuke Mitamura (Kyowa Kirin Co., Ltd.)
TBD
Yuma Yoshioka (Keio University, Kanagawa)
Angulin-1/LSR is a novel isoform-dependent negative regulator of vasculogenic mimicry by breast cancer cells
Satoshi Kawano (Eisai Co., Ltd., Ibaraki)
Effect of tasurgratinib as an orally available FGFR1-3 inhibitor on resistance to a CDK4/6 inhibitor and endocrine therapy in ER(+)/HER2(-) breast cancer preclinical models
Ryota Nakamura (Kyoto Prefectural University of Medicine, Kyoto)
Development of a curative initial combination therapy targeting EGFR, AXL, and FGFR for EGFR-mutated non-small cell lung cancer
Takahiro Utsumi (Cancer Chemotherapy Center, JFCR, Tokyo and Kyushu University, Fukuoka)
GAS6 from macrophages and MMP11 positive fibroblasts induces AXL-mediated drug resistance in ALK-rearranged NSCLC
Wei Xinzhao (Cancer Chemotherapy Center, JFCR, Tokyo)
TBD
Toshifumi Hoki (MSD K.K., Tokyo)
INTerpath-001 Trial in Progress: Pembrolizumab With V940 (mRNA-4157) Versus Pembrolizumab With Placebo for Adjuvant Treatment of High-Risk Stage II-IV Melanoma
Tetsuo Mashima (Cancer Chemotherapy Center, JFCR, Tokyo)
Identification of predictive biomarkers for tankyrase inhibitor sensitivity in colorectal cancer patient-derived cell models
December 12
Session III: Precision medicine and potential of whole genomic data
Chairpersons: Hiromichi Ebi (Aichi Cancer Center Research Institute, Aichi) ,
Isamu Okamoto (Kyushu University, Fukuoka)
9:00-9:40
Aparna Parikh (Massachusetts General Hospital Cancer Center, Boston, MA, USA)
ct-DNA guides adjuvant therapy in coloreactal cancer
9:40-10:10
Tatsuhiro Shibata (The University of Tokyo, Tokyo)
Driver gene landscape of gastric cancer
10:10-10:40
Yoshiaki Nakamura (National Cancer Center Hospital East, Chiba)
Precision oncology revolution: SCRUM- MONSTAR initiative
10:40-10:50
Discussion
Meet-the-Expert
Chairperson: Ryohei Katayama (Cancer Chemotherapy Center, JFCR, Tokyo)
10:50-11:40
Susan Bullman (MD Anderson Cancer Center, Houston, TX, USA)
Mapping tumor-infiltrating microbes: Microniches to single cells in the tumor microenvironment
Luncheon Seminar "Clinical implementation of AI-designed cancer vaccines"
(Supported by NEC )
Chairperson: Shigehisa Kitano (Cancer Institute Hospital of JFCR)
11:50-12:20
Kaïdre Bendjama (NEC OncoImmunity AS, Oslo, Norway)
AI-driven immune system modelisation for neoantigen target identification and vaccine design
12:20-12:50
Lina Simaškaitė-Pužauskienė (The Hospital of Lithuanian University of Health Sciences, Kaunas Clinics, Lithuania)
NECVAX-NEO1, an oral bacteria-based cancer vaccine targeting personalized neoantigens in solid tumor patients – Interim data
Session IV: Microbiome and Cancer
Chairpersons: Ryan Corcoran (Massachusetts General Hospital Cancer Center, Boston, MA, USA),
Masanobu Oshima (Kanazawa University, Ishikawa)
13:00-13:40
Arielle Elkrief (University of Montreal, Montréal, Québec, Canada)
The role of the gut microbiome in the response to immunotherapy in NSCLC and melanoma
13:40-14:10
Shohei Koyama (National Cancer Center Research Institute, Tokyo )
Mechanisms of immunostimulatory effects by specific gut microbial strain on the tumor immune microenvironment
14:10-14:40
Naoko Ohtani (Osaka Metoropolitan University, Osaka)
The role of gut microbiota in modulating the secretome of senescent CAFs in tumor microenvironment
14:40-14:50
Discussion
14:50-15:00
Break
Session V: Other targets and drugs
Chairpersons: Liron Bar-Peled (Massachusetts General Hostpital, Boston, MA, USA),
Noriko Goto (Kanazawa University, Ishikawa)
15:00-15:30
Shigehisa Kitano (Cancer Institute Hospital of JFCR, Tokyo)
Novel HER2-targeted therapy for solid tumor
15:30-16:00
Naoki Kimura (Chugai Pharmaceutical Co., Ltd., Kanagawa)
Therapeutic potency of SAIL66, a next generation T cell engager, against CLDN6-positive tumor
16:00-16:40
David Kerstein (IDRx, Plymouth, MA, USA)
The KIT inhibitor IDRX-42 shows promising activity in 2nd and later-line gastrointestinal stromal tumors (GIST): results of a phase 1 study (StrateGIST 1)
16:40-16:50
Discussion
Closing Remark
16:50-17:00
Yves Pommier (National Cancer Institute, NIH, Bethesda, MD, USA)
Closing remark